OpenURL Connection Search

Select item for more details and to access through your institution.

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).
Published in:
Cancer Immunology, Immunotherapy, 2023, v. 72, n. 7, p. 2257, doi. 10.1007/s00262-023-03412-8
By:
- Liu, Si-Yang;
- Chen, Qixun;
- Zhou, Chengzhi;
- Zhang, Huizhong;
- Li, Wen;
- Chen, Jianhua;
- Hu, Jian;
- Wu, Lin;
- Chen, Qunqing;
- Dai, Qiangsheng;
- Shan, Jian-Zhen;
- Xu, Fei;
- Liu, Si-Yang Maggie;
- Wu, Yi-Long
Publication type:
Article
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer.
Published in:
Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00470-z
By:
- Liu, Si-Yang Maggie;
- Chen, Cunte;
- Zhang, Yi-Kai;
- Zhong, Wen-Zhao;
- Wu, Yi-Long;
- Liu, Si-Yang;
- Li, Yangqiu
Publication type:
Article
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.
Published in:
Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00465-w
By:
- Ye, Dingwei;
- Desai, Jayesh;
- Shi, Jingwen;
- Liu, Si-Yang Maggie;
- Shen, Wei;
- Liu, Tengfei;
- Shi, Yang;
- Wang, Dan;
- Liang, Liang;
- Yang, Silu;
- Ma, Xiaopeng;
- Jin, Wei;
- Zhang, Pei;
- Huang, Ruiqi;
- Shen, Zhirong;
- Zhang, Yun;
- Wu, Yi-Long
Publication type:
Article
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.
Published in:
Cancers, 2023, v. 15, n. 1, p. 302, doi. 10.3390/cancers15010302
By:
- Jie, Guang-Ling;
- Peng, Lun-Xi;
- Zheng, Mei-Mei;
- Sun, Hao;
- Wang, Song-Rong;
- Liu, Si-Yang Maggie;
- Yin, Kai;
- Chen, Zhi-Hong;
- Tian, Hong-Xia;
- Yang, Jin-Ji;
- Zhang, Xu-Chao;
- Tu, Hai-Yan;
- Zhou, Qing;
- Wong, Catherine C. L.;
- Wu, Yi-Long
Publication type:
Article
Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy.
Published in:
Molecular Oncology, 2023, v. 17, n. 8, p. 1581, doi. 10.1002/1878-0261.13439
By:
- Tu, Hai‐Yan;
- Yin, Kai;
- Zhao, Xiaotian;
- Ke, E‐E;
- Wu, Si‐Pei;
- Li, Yang‐Si;
- Zheng, Mei‐Mei;
- Liu, Si‐Yang Maggie;
- Xu, Chong‐Rui;
- Sun, Yue‐Li;
- Lin, Jia‐Xin;
- Bai, Xiao‐Yan;
- Zhang, Yi‐Chen;
- Zhou, Qing;
- Yang, Jin‐Ji;
- Zhong, Wen‐Zhao;
- Wang, Bing‐Chao;
- Zhang, Xu‐Chao;
- Zhu, Dongqin;
- Yang, Lingling
Publication type:
Article
Targeted Therapy in Early Stage Non-small Cell Lung Cancer.
Published in:
2022
By:
- Liu, Si-Yang;
- Liu, Si-Yang Maggie;
- Zhong, Wen-Zhao;
- Wu, Yi-Long
Publication type:
journal article
Emerging evidence and treatment paradigm of non-small cell lung cancer.
Published in:
Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01436-2
By:
- Liu, Si-Yang Maggie;
- Zheng, Mei-Mei;
- Pan, Yi;
- Liu, Si-Yang;
- Li, Yangqiu;
- Wu, Yi-Long
Publication type:
Article

Found: 7

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer.

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.

Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy.

Targeted Therapy in Early Stage Non-small Cell Lung Cancer.

Emerging evidence and treatment paradigm of non-small cell lung cancer.